tbuckley/cabot-search huggingface dataset:
The Kinetics of Transforming Growth Factor beta1 mRNA Expression and Its Serum Concentration in Graft-Versus-Host Disease After Allogeneic Hemopoietic Stem Cell Transplantation for Myeloid Leukemias.
Authors: Patrycja Zielinska, Grzegorz Helbig, Agata Wieczorkiewicz, Slawomira Krzemien
Journal: Blood (2009)
Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma
Authors: Sun-Young Kong, Yosef Landesman, Jana Jakubikova, Michael A. Sellitto, Antonia Cagnetta, Michele Cea, Michelle C. Chen, Francesca Cottini, Douglas W. McMillin, Chirag Acharya, William Senapedis, Sharon Shacham, Michael Kauffman, Dilara McCauley, Jean-Richard Saint-Martin, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson, Yu-Tzu Tai
Journal: Blood (2011)
Understanding the Immunomodulatory Effect of Mesenchymal Stem Cell Infused In Transplanted Patients with Steroid-Refractory GvHD
Authors: Erica Dander, Giovanna Lucchini, Paola Vinci, Martino Introna, Sonia Bonanomi, Adriana Balduzzi, Giuseppe Gaipa, Paolo Perseghin, Francesca Masciocchi, Chiara Capelli, Josée Golay, Alessandra Algarotti, Alessandro Rambaldi, Attilio Rovelli, Andrea Biondi, Ettore Biagi, Giovanna D'Amico
Journal: Blood (2010)
Noninvasive proteome analysis of psoriatic stratum corneum reflects pathophysiological pathways and is useful for drug profiling
Authors: B. Méhul, G. Laffet, A. Séraïdaris, L. Russo, P. Fogel, I. Carlavan, C. Pernin, P. Andres, C. Queille-Roussel, J.J. Voegel
Journal: British Journal of Dermatology (2017)

BackgroundProtein expression is disturbed in the psoriatic stratum corneum (SC). Noninvasive methods for the description of pathophysiological changes and drug profiling in psoriasis are desirable.
Exploratory Introduction of Cognitive Computing to Clinical Sequencing in Hematological Malignancies
Authors: Kazuaki Yokoyama, Nozomi Yusa, Mika Itoh, Asako Suzuki, Sosuke Nakamura, Miho Ogawa, Koji Jimbo, Masayuki Kobayashi, Toyotaka Kawamata, Takaaki Konuma, Rika Kasajima, Hiroaki Yui, Eigo Shimizu, Takahiko Koyama, Nobuhiro Ohno, Yoichi Imai, Satoshi Takahashi, Kaoru Uchimaru, Rui Yamaguchi, Seiya Imoto, Yoichi Furukawa, Satoru Miyano, Arinobu Tojo
Journal: Blood (2016)
The unclosing premature mortality gap in gout: a general population-based study
Authors: Mark C Fisher, Sharan K Rai, Na Lu, Yuqing Zhang, Hyon K Choi
Journal: Annals of the Rheumatic Diseases (2017)

Gout, the most common inflammatory arthritis, is associated with premature mortality. Whether this mortality gap has improved over time, as observed in rheumatoid arthritis (RA), is unknown.Using an electronic medical record database representative of the UK general population, we identified incident gout cases and controls between 1999 and 2014. The gout cohort was divided based on year of diagnosis into early (1999-2006) and late (2007-2014) cohorts. We compared the mortality rates and HRs, adjusting for potential confounders between the cohorts. We conducted sensitivity analyses among patients with gout who received at least one prescription for urate-lowering therapy, which has been found to have a validity of 90%.In both cohorts, patients with gout showed similar levels of excess mortality compared with their corresponding comparison cohort (ie, 29.1 vs 23.5 deaths/1000 person-years and 23.0 vs 18.8 deaths/1000 person-years in the early and late cohorts, respectively). The corresponding mortality HRs were 1.25 (95% CI 1.21 to 1.30) and 1.24 (95% CI 1.20 to 1.29), and the multivariable HRs were 1.10 (95% CI 1.06 to 1.15) and 1.09 (95% CI 1.05 to 1.13), respectively (both p values for interaction >0.72). Our sensitivity analyses showed similar findings (both p values for interaction >0.88).This general population-based cohort study indicates that the level of premature mortality among patients with gout remains unimproved over the past 16 years, unlike RA during the same period. This unclosing premature mortality gap calls for improved management of gout and its comorbidities.
Family-Associated Monoclonal B Lymphocytosis Is Commonly Oligoclonal and Expresses Markers Associated with Adverse Risk in CLL
Authors: Mark C Lanasa, Sallie D Allgood, Susan L. Slager, Nicola Camp, Logan Spector, Laura Rassenti, Neil E. Kay, Jon P Gockerman, Alicia Volkheimer, Barbara K Goodman, Sara Strom, Timothy Call, James Cerhan, Jose F Leis, Lynn Goldin, Gerald Marti, J Brice Weinberg, Neil Caporaso, Marc C. Levesque
Journal: Blood (2008)
Clonal Analysis of Human Bone Marrow CD34+ Cells Edited By BCL11A-Targeting Zinc Finger Nucleases Reveals Clinically Relevant Levels of Fetal Globin Expression in Edited Erythroid Progeny
Authors: Kai-Hsin Chang, Timothy Sullivan, Mei Liu, Xiao Yang, Chao Sun, Benjamin Vieira, Ming Zhang, Vu P. Hong, Kai Chen, Sarah Smith, Siyuan Tan, Andreas Reik, Fyodor D Urnov, Edward J. Rebar, Olivier Danos, Haiyan Jiang
Journal: Blood (2015)
Germ-Line and Somatic Mutations in Familial Myeloproliferative Neoplasms (MPNs). a Pilot Study
Authors: Sucha Nand, Manuel O. Diaz, David E. Marinier, Mark A. Walshauser, Amy B Rosenfeld, Laura C Michaelis, Patrick J Stiff, Xiaowu Gai
Journal: Blood (2014)
Stepwise examination of prostate clinical trials participation to reduce accrual barriers.
Authors: Dare Olatoye, Michael Anthony Carducci, Norma Kanarek
Journal: Journal of Clinical Oncology (2012)

157 Background: Adequate and representative enrollment in therapeutic clinical trials is important to an NCI cancer center. Clinical trial participation is a string of 6 sequential patient and physician decisions beginning with an available therapeutic trial to enrollment in the trial. Opportunities for participation may be lost at any one of these steps. The objective of this study was to calculate transitional probabilities that measure patient, especially minority patient, accrual to clinical trials at the Sidney Kimmel Comprehensive Cancer Center and to describe the barriers for those dropping out at each step. Methods: Records for “first visit” medical oncology patients seen by three SKCCC physicians from January to April 2010 were abstracted. Prostate cancer case reports from the hospital cancer registry and a medical record review provided age, race, Hispanic ethnicity, place of residence, tumor characteristics, and prior treatment history. At each transition step, we calculated the proportion of patients who remained enrollable. Results: Overall, prostate cancer clinical trial participation was 17% (16/94). Minority accrual was similar to Caucasian accrual at 19% and 17% , respectively. Retention at each step of trial participation was highest for “discussed” (98%), “enrolled” (94%), “eligibility” for available trials (79%), and “consented” (71%). Two bottlenecks were qualitatively identified: “trial availability” (65%) and “patient interest” (51%). Forty-two percent of those for whom there was no trial available were older than 70 years and 33% were patients with rising PSA after local therapy and hormone-naïve. The “patient interest” step was shaped primarily by disinterest due to distance to SKCCC (83%). Conclusions: For prostate cancer patients, recruitment to medical oncology clinical trials is robust. Minority patients however are only 17% of all patients seen and half drop out when no trial is available and half of those remaining judged distance to be a problem (hence, no interest). This study approach has clarified which factors are likely to be barriers to participation and is likely useful to making adjustments that can reduce identified barriers by adding to trial portfolio as an example.
Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results
Authors: Michael B Tomblyn, Thomas E. Witzig, Andrew L Himelstein, Rebecca Elstrom, Ebenezer A Kio, Robert M Sharkey, Jonathan Rojo, William Wegener, David M Goldenberg
Journal: Blood (2012)
Effects of Childhood Asthma on the Development of Obesity among School-aged Children
Authors: Zhanghua Chen, Muhammad T. Salam, Tanya L. Alderete, Rima Habre, Theresa M. Bastain, Kiros Berhane, Frank D. Gilliland
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Rationale: Asthma and obesity often occur together in children. It is unknown whether asthma contributes to the childhood obesity epidemic.Objectives: We aimed to investigate the effects of asthma and asthma medication use on the development of childhood obesity.Methods: The primary analysis was conducted among 2,171 nonobese children who were 5–8 years of age at study enrollment in the Southern California Children's Health Study (CHS) and were followed for up to 10 years. A replication analysis was performed in an independent sample of 2,684 CHS children followed from a mean age of 9.7 to 17.8 years.Measurements and Main Results: Height and weight were measured annually to classify children into normal, overweight, and obese categories. Asthma status was ascertained by parent- or self-reported physician-diagnosed asthma. Cox proportional hazards models were fitted to assess associations of asthma history with obesity incidence during follow-up. We found that children with a diagnosis of asthma at cohort entry were at 51% increased risk of developing obesity during childhood and adolescence compared with children without asthma at baseline (hazard ratio, 1.51; 95% confidence interval, 1.08–2.10) after adjusting for confounders. Use of asthma rescue medications at cohort entry reduced the risk of developing obesity (hazard ratio, 0.57; 95% confidence interval, 0.33–0.96). In addition, the significant association between a history of asthma and an increased risk of developing obesity was replicated in an independent CHS sample.Conclusions: Children with asthma may be at higher risk of obesity. Asthma rescue medication use appeared to reduce obesity risk independent of physical activity.
Platelets Lacking Sialic Acid Clear Rapidly from the Circulation Due to Ingestion by Asialoglycoprotein Receptor-Expressing Liver Macrophages and Hepatocytes.
Authors: Anne Louise Soerensen, Hans H. Wandall, Sunita Patel, Jennifer Richardson, Joseph Italiano, Henrik Clausen, Thomas P. Stossel, John H. Hartwig, Karin M. Hoffmeister
Journal: Blood (2006)
Several Somatic Mutations of JAK2 Exon 12 Are Found in Patients with a JAK2 (V617F)-Negative Myeloproliferative Disorder That Is Mainly Characterized by Erythrocytosis.
Authors: Daniela Pietra, Sai Li, Angela Brisci, Francesco Passamonti, Elisa Rumi, Alexandre Theocharides, Heinz Gissingler, Robert Kralovics, Laura Cremonesi, Radek C. Skoda, Mario Cazzola
Journal: Blood (2007)
Assessing adherence to the European Organization for Research and Treatment of Cancer (EORTC) guidelines for the use of erythropoiesis-stimulating agents in cancer patients
Authors: J. Castro, J. M. Muñoz-Langa, A. Covas, J. A. Gasquet
Journal: Journal of Clinical Oncology (2008)

20696 Background: Anemia is a common symptom in cancer patients and has a considerable impact on patient quality of life (QoL). According to the European Cancer Anemia Survey, anemia was treated in only 38.9% of patients. Erythropoiesis-stimulating agents (ESAs) are widely used for the treatment of the chemotherapy-induced anemia (CIA). The European Organization for Research and Treatment of Cancer (EORTC) recently published guidelines for the use of ESAs in cancer patients, but actual adherence to these guidelines in clinical practice is unknown. Methods: Between March and July 2007, 16 working sessions were held and 179 Spanish oncologists were consulted to assess their adherence to the EORTC guidelines (update 2006)for the use of ESAs. In all sessions, a preliminary presentation about these guidelines was given, followed by a structured discussion that was facilitated by a moderator using an organized, brain storming work method (Metaplan). Results: Over 90% of oncologists agreed that the two major goals of ESA therapy are improvement of QoL and prevention of transfusions; 70% consider that CIA treatment with ESA should be initiated at a hemoglobin (Hb) level of 10–11g/dL. ESAs are administered every week (59%) or every three weeks (33%). In the opinion of 64% of respondents, the target Hb concentration should be 12–13 g/dL. Altogether 45% of oncologists use ESA in anemic patients with an Hb level of <11.9 g/dL to prevent a further decline in Hb. All participants agreed with the use of fixed doses of ESAs. Intravenous iron supplementation is low (5%). Conclusions: These study results show good adherence to the current EORTC guidelines in Spain, but action to increase adherence may improve patient outcomes. The main discrepancies are the use of intravenous iron and ESA in patients with Hb <11.9 g/dL. This study was supported by Amgen S.A. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Amgen Amgen
Short Synthetic β‐Sheet Antimicrobial Peptides for the Treatment of Multidrug‐Resistant <i>Pseudomonas aeruginosa</i> Burn Wound Infections
Authors: Guansheng Zhong, Junchi Cheng, Zhen Chang Liang, Liang Xu, Weiyang Lou, Chang Bao, Zhan Yuin Ong, Huihui Dong, Yi Yan Yang, Weimin Fan
Journal: Advanced Healthcare Materials (2017)

Pseudomonas aeruginosa is often implicated in burn wound infections; its inherent drug resistance often renders these infections extremely challenging to treat. This is further compounded by the problem of emerging drug resistance and the dearth of novel antimicrobial drug discovery in recent years. In the perennial search for effective antimicrobial compounds, the authors identify short synthetic β-sheet folding peptides, IRIKIRIK (IK8L), IRIkIrIK (IK8-2D), and irikirik (IK8D) as prime candidates owing to their high potency against Gram-negative bacteria. In this study, the peptides are first assayed against 20 clinically isolated multidrug-resistant P. aeruginosa strains in comparison with the conventional antibiotics imipenem and ceftazidime, and IK8L is demonstrated to be the most effective. IK8L also exhibits superior antibacterial killing kinetics compared to imipenem and ceftazidime. From transmission electron microscopy, confocal microscopy, and protein release analyses, IK8L shows membrane-lytic antimicrobial mechanism. Repeated use of IK8L does not induce drug resistance, while the bacteria develop resistance against the antibiotics after several times of treatment at sublethal doses. Analysis of mouse blood serum chemistry reveals that peptide does not induce systemic toxicity. The potential utility of IK8L in the in vivo treatment of P. aeruginosa-infected burn wounds is further demonstrated in a mouse model.
Inhibitory Effect of Monoclonal Antibodies Against CXCR3-B NH2-Terminus on the Proliferation of U937 Cells.
Authors: Yuan Gao, Zhi-Cheng Chen, Li Liu, Jin-Ju Yang, Xiao-Lan Liu, Yong Chen, Jian-En Gao, Chaoyan Liu, Gian Paolo Visentin, Qi-Hong Sun
Journal: Blood (2005)
Autologous Stem Cell Transplantation Followed by Reduced Intensity Allogeneic Stem Cell Transplantation (Tandem Transplantation) as Treatment for Advanced Resistant Hodgkin’s Lymphoma Patients. A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT).
Authors: Ivan Alvarez, Carme Canals, Goli Taghipour, Angelo M. Carella, Yves Beguin, Didier Blaise, Danielle Lazzlo, Bernardino Aillone, Jean H. Bourhis, Lucca Castagna, Paolo Corradini, Paolo Iacopino, Giuseppe Milone, Pedro Pimentel, Nigel H. Russell, Pierre Zachee, Anna Sureda
Journal: Blood (2006)
Excision repair cross-complementing 1 (ERCC1) and survival in advanced bladder cancer: Confirmatory results using immunohistochemistry
Authors: M. Guix, L. Lema, J. Lloreta, F. Rojo, C. Suárez, J. Carles, J. de la Cruz, M. Sánchez-Carbayo, J. Albanell, J. Bellmunt
Journal: Journal of Clinical Oncology (2009)

5025 Background: DNA damaging agents are the backbone of combination chemotherapy regimens for the treatment of advanced bladder cancer. We hypothesized that levels of DNA repair genes such as ERCC1 could predict survival in patients receiving platinum based therapy. Our previous work (Bellmunt J et al, Ann Oncol. 2007) showed that survival was significantly higher in advanced bladder cancer patients with low gene expression levels of ERCC1 measured by RT-qPCR (25.4 versus 15.4 months; p = 0.03). We aimed to confirm these findings using immunohistochemistry (IHC) in an independent cohort of advanced bladder cancer patients treated with cisplatin-based chemotherapy at our institution. Methods: Formalin-fixed paraffin-embedded tumor tissue was available from 51 patients. IHC stains for ERCC1 protein levels were scored as percentage and intensity of positive cells. ERCC1 staining was considered positive if detected in ≥1% tumor cells. The Kaplan-Meier method was used to calculate survival and the Cox proportional hazards model was used to examine the prognostic value of protein expression levels. Results: ERCC1 staining was negative in 60% of patients, weakly positive (1–10% positive cells) in 21% and strongly positive (&gt;10% positive cells) in 19%. Median overall survival for all patients was 14.4m (95% CI 6.7–16.1m). Median disease-specific survival was significantly higher in patients negative for ERCC1 by IHC (12.6m versus 8.6m; p = 0.032). Conclusions: Our results using the more simple IHC technique confirm the prognostic value of ERCC1 expression in advanced bladder cancer. Patients with high expression of ERCC1 by IHC have a worse disease-specific survival than patients with no expression. A correlative study of IHC and RT-qPCR in both sets of samples is ongoing. No significant financial relationships to disclose.
High Plasma Lysyloxidase Concentration Is Associated with Inferior Outcome and Extramedullary Disease in Patients with Acute Myeloid Leukemia
Authors: Friedrich Stöolzel, Thomas Illmer, Claudia Dill, Michael Kramer, Brigitte Mohr, Christian Thiede, Uwe Platzbecker, Johannes Schetelig, Christoph Röllig, Martin Bornhäuser, Gerhard Ehninger, Markus Schaich
Journal: Blood (2011)
Analytical Validation of Patient-Specific PCR-Based MRD Assessment for Use As a Primary Endpoint in CLL Clinical Trials
Authors: Anke Schilhabel, Henrik Knecht, Anton W. Langerak, Jacques J.M. van Dongen, Michael Kneba, Jill Ray, Elizabeth Punnoose, Doris Kim, Thomas Haberberger, Coen Bernaards, Yuda Zhu, Sock-Cheng Lewin-Koh, Matthias Ritgen
Journal: Blood (2015)
FLT3 Is Up-Regulated in Blast Crisis of Chronic Myeloid Leukemia and Combination of Small Interference RNA of FLT3 and Gleevec (STI571) Synergistically Induces the Apoptosis in K562 Cells.
Authors: Young Y. Lee, Kwang-Sung Ahn, Sung-Soo Yoon, Jung H. Choi, Byoung B. Park, Byoung K. Kim
Journal: Blood (2007)
Tetraspanin CD9 Inhibits ADAM17-Mediated LR11 Shedding In Leukemia Cells
Authors: Shokichi Tsukamoto, Masahiro Takeuchi, Takeharu Kawaguchi, Emi Togasaki, Atsuko Yamazaki, Yasumasa Sugita, Tomoya Muto, Shio Sakai, Yusuke Takeda, Chikako Ohwada, Naomi Shimizu, Emiko Sakaida, Keigo Nishii, Meizi Jiang, Tohru Iseki, Koutaro Yokote, Hideaki Bujo, Chiaki Nakaseko
Journal: Blood (2013)
Response to Open Peer Commentaries on “Irrational Exuberance: Cardiopulmonary Resuscitation as Fetish”
Authors: Philip M. Rosoff, Lawrence J. Schneiderman
Journal: The American Journal of Bioethics (2017)

We appreciate the opportunity to respond to the numerous open peer commentaries in response to our article, “Irrational Exuberance: Cardiopulmonary Resuscitation as Fetish” (Rosoff and Schneiderman...
In Vitro and In Vivo Antileukemic Effects of the mTOR-Targeting Drug Rapamycin in Patients with Imatinib-Resistant CML.
Authors: Matthias Mayerhofer, Alexandra Boehm, Karl J. Aichberger, Harald Esterbauer, Sophia Derdak, Winfried F. Pickl, Christian Sillaber, Peter Valent
Journal: Blood (2005)
Forodesine in Patients with Refractory/Relapsed T-ALL Can Induce Prolonged Stable Remission with Minimal Toxicity before and after Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Mattias Stelljes, Joachim Kienast, Björna Berning, Nicola Gokbuget, Dieter Hoelzer, Gerda Silling, Wolfgang E. Berdel, Gary Van Houten Dahl, Debra Schissel, Molly Hemenway, Lia Gore
Journal: Blood (2006)
Breast Cancer Therapy in the Elderly
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML).
Authors: Victor M. Rivera, Qihong Xu, Frank Wang, Joseph Snodgrass, Thomas O’Hare, Amie S. Corbin, Jeffrey Keats, Sarah Lamore, Yaoyu Ning, Scott Wardwell, Karin Russian, Marc Broudy, William C. Shakespeare, Brian J. Druker, John D. Iuliucci, Tim Clackson
Journal: Blood (2007)
TP53 Mutations, the Most Frequent Genetic Lesion in Richter Syndrome, Represent An Independent Predictor of Survival Post Transformation.
Authors: Davide Rossi, Valeria Spina, Clara Deambrogi, Marco Lucioni, Luca Arcaini, Gabrielle B. Rocque, Jeffrey T. Malik, Julie E. Chang, Ekaterina Chigrinova, Josep F. Nomdedeu, Francesco Forconi, Roberto Marasca, Caroline Besson, Vincenzo Canzonieri, Marco Paulli, Valter Gattei, Francesco Bertoni, Ken H. Young, Gianluca Gaidano
Journal: Blood (2009)